IMPRINT
Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheibio.com
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
SOCIAL MEDIA
© 2020
Contribution of Pantarhei Oncology to the 18th World Congress of the IAHR
/in News /by Pantarhei BioscienceContribution of Pantarhei Oncology to the 18th World Congress of the International Academy of the Human Reproduction (IAHR), April 3-6, 2019 in Dublin by an invited lecture of Herjan Coelingh Bennink
On Thursday April 4, 2019, a key lecture entitled “Estrogens, Estetrol and Breast Cancer” was given by Herjan Coelingh Bennink, President of Pantarhei Oncology during a scientific session “Oncology, Breast and Gynecological Surgery”. The session was chaired by by Andrea Genazzani. For more information, please read the abstract.
Interview Herjan Coelingh Bennink in de Volkskrant “Een anticonceptiepil mét testosteron moet man en vrouw seksueel gelijkwaardiger maken.”
/in News /by Pantarhei BioscienceNa twintig jaar onderzoek van Pantarhei Bioscience komt dankzij farmaceut Gedeon Richter een bijzondere anticonceptiepil dichter bij de vrouw. De Volkskrant schetst in een interview met Herjan Coelingh Bennink de geschiedenis tot nu toe in een artikel getiteld “Een anticonceptiepil mét testosteron moet man en vrouw seksueel gelijkwaardiger maken.”
Lees hier het hele artikel
Gedeon Richter and Pantarhei signed a license and supply agreement for commercialisation of a novel combined oral contraceptive
/in News /by Pantarhei BioscienceGedeon Richter Plc. and Pantarhei Bioscience BV today announced that they have entered into a license and supply agreement to commercialise Pantarhei’s combined oral contraceptive (COC), containing 30 µg ethinyl estradiol, 150 µg levonorgestrel and 50 mg dehydroepiandrosterone (DHEA). The product is under development with successfully completed Phase II trials and is ready for further clinical studies to obtain marketing approval. The geographic scope of the agreement covers Europe, Russia, Latin America and Australia.
Read more: Press Release GedeonRichter – Pantarhei February 4, 2019